ReviewAAPS PharmSciTech2026
Solid Lipid Nanoparticles Based Dry Powder Inhalers for Enhanced Drug Delivery Against Lung Diseases.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global incidence of lung diseases associated with high mortality and morbidity rates is projected to rise in the coming years. Conventional therapies face limitations such as low bioavailability and systemic side effects with oral administration, as well as poor patient compliance and frequent dosing with traditional inhalers. These shortcomings have created an urgent need for novel pulmonary drug delivery systems. In recent years, nanoparticulate drug carriers have gained significance for their potential to enable targeted lung delivery and reduced dosing frequency. Among them, solid lipid nanoparticles (SLNs) have attracted considerable attention due to their biocompatible and biodegradable structures, controlled release capabilities, organic solvent-free production processes and favorable aerodynamic behavior. This review provides a comprehensive perspective to guide the rational design of SLN-based dry powder inhaler (DPI) systems by integrating formulation strategies, production techniques, surface functionalization, and DPI development, with the goal of enhancing therapeutic outcomes in respiratory diseases such as cancer, infections, chronic obstructive pulmonary disease, and cystic fibrosis.
Indexed as
Identifiers
42717150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.